Carregant...
SUN-LB030 Empagliflozin Causing Euglycemic Diabetic Ketoacidosis
Background: Empagliflozin is a sodium glucose co-transporter 2 (SGLT-2) inhibitor that works in the proximal renal tubules reducing resorption of glucose and increasing urinary glucose excretion. It effectively lowers glycated hemoglobin (HbA1C) values and reduces risks of adverse cardiovascular eve...
Guardat en:
| Publicat a: | J Endocr Soc |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Endocrine Society
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6552746/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SUN-LB030 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|